Keywords
Last Name
Institution

AARON E FOSTER

TitleAdjunct Assistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
DivisionPediatrics-Hem/Onc Cell & Gene The
AddressONE BAYLOR PLAZA
HOUSTON TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Foster AE, Mahendravada A, Shinners NP, Chang WC, Crisostomo J, Lu A, Khalil M, Morschl E, Shaw JL, Saha S, Duong MT, Collinson-Pautz MR, Torres DL, Rodriguez T, Pentcheva-Hoang T, Bayle JH, Slawin KM, Spencer DM. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40. Mol Ther. 2017 Jul 08. PMID: 28697888.
      View in: PubMed
    2. Figueroa ER, Yan JS, Chamberlain-Simon NK, Lin AY, Foster AE, Drezek RA. Systematically probing the bottom-up synthesis of AuPAMAM conjugates for enhanced transfection efficiency. J Nanobiotechnology. 2016; 14:24. PMID: 27029613; PMCID: PMC4815207.
    3. Galvan DL, O'Neil RT, Foster AE, Huye L, Bear A, Rooney CM, Wilson MH. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. PLoS One. 2015; 10(10):e0140744. PMID: 26473608.
      View in: PubMed
    4. Almeida JP, Lin AY, Figueroa ER, Foster AE, Drezek RA. In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. Small. 2015 Mar 25; 11(12):1453-9. PMID: 25354691; PMCID: PMC4373976.
    5. Foster AE, Song XT. Modification of T lymphocytes to express tumor antigens. Methods Mol Biol. 2014; 1139:169-76. PMID: 24619679.
      View in: PubMed
    6. Almeida JP, Drezek RA, Foster AE. Controlling melanoma at local and systemic levels: is a combination of ablative therapy and immunotherapy the way forward? Immunotherapy. 2014; 6(2):109-11. PMID: 24491082; PMCID: PMC4025948.
    7. Figueroa ER, Lin AY, Yan J, Luo L, Foster AE, Drezek RA. Optimization of PAMAM-gold nanoparticle conjugation for gene therapy. Biomaterials. 2014 Feb; 35(5):1725-34. PMID: 24286816; PMCID: PMC3906732.
    8. Almeida JP, Lin AY, Langsner RJ, Eckels P, Foster AE, Drezek RA. In vivo immune cell distribution of gold nanoparticles in naïve and tumor bearing mice. Small. 2014 Feb 26; 10(4):812-9. PMID: 24115675; PMCID: PMC3962812.
    9. Glasgow SM, Laug D, Brawley VS, Zhang Z, Corder A, Yin Z, Wong ST, Li XN, Foster AE, Ahmed N, Deneen B. The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci. 2013 Aug 14; 33(33):13560-8. PMID: 23946414; PMCID: PMC3742938.
    10. Bear AS, Kennedy LC, Young JK, Perna SK, Mattos Almeida JP, Lin AY, Eckels PC, Drezek RA, Foster AE. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS One. 2013; 8(7):e69073. PMID: 23935927; PMCID: PMC3720863.
    11. Doherty JE, Woodard LE, Bear AS, Foster AE, Wilson MH. An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression. FASEB J. 2013 Sep; 27(9):3753-62. PMID: 23752206; PMCID: PMC3752539.
    12. Lin AY, Almeida JP, Bear A, Liu N, Luo L, Foster AE, Drezek RA. Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One. 2013; 8(5):e63550. PMID: 23691064; PMCID: PMC3655178.
    13. Lin AY, Lunsford J, Bear AS, Young JK, Eckels P, Luo L, Foster AE, Drezek RA. High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro. Nanoscale Res Lett. 2013; 8(1):72. PMID: 23402570; PMCID: PMC3579702.
    14. Kang P, Lee HK, Glasgow SM, Finley M, Donti T, Gaber ZB, Graham BH, Foster AE, Novitch BG, Gronostajski RM, Deneen B. Sox9 and NFIA coordinate a transcriptional regulatory cascade during the initiation of gliogenesis. Neuron. 2012 Apr 12; 74(1):79-94. PMID: 22500632; PMCID: PMC3543821.
    15. Bear AS, Cruz CR, Foster AE. T cells as vehicles for cancer vaccination. J Biomed Biotechnol. 2011; 2011:417403. PMID: 22131805; PMCID: PMC3205726.
    16. Almeida JP, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine (Lond). 2011 Jul; 6(5):815-35. PMID: 21793674.
      View in: PubMed
    17. Kennedy LC, Bear AS, Young JK, Lewinski NA, Kim J, Foster AE, Drezek RA. T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res Lett. 2011; 6(1):283. PMID: 21711861; PMCID: PMC3211348.
    18. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8. PMID: 20842059; PMCID: PMC2998197.
    19. Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther. 2010 Nov; 18(11):2006-17. PMID: 20842106; PMCID: PMC2990520.
    20. Shafer JA, Cruz CR, Leen AM, Ku S, Lu A, Rousseau A, Heslop HE, Rooney CM, Bollard CM, Foster AE. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010 May; 51(5):870-80. PMID: 20367572; PMCID: PMC2991134.
    21. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010 Mar; 24(3):563-72. PMID: 20072155; PMCID: PMC2836398.
    22. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009; 8:106. PMID: 19922650; PMCID: PMC2784756.
    23. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, June CH, Rooney CM, Wilson MH. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother. 2009 Oct; 32(8):826-36. PMID: 19752751; PMCID: PMC2796278.
    24. Kaka AS, Shaffer DR, Hartmaier R, Hartmeier R, Leen AM, Lu A, Bear A, Rooney CM, Foster AE. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother. 2009 Sep; 32(7):726-36. PMID: 19561536; PMCID: PMC2790367.
    25. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402. PMID: 19377047; PMCID: PMC2710932.
    26. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8. PMID: 19259067; PMCID: PMC2835146.
    27. Foster AE, Kwon S, Ke S, Lu A, Eldin K, Sevick-Muraca E, Rooney CM. In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye. Appl Opt. 2008 Nov 1; 47(31):5944-52. PMID: 19122737; PMCID: PMC2744150.
    28. Foster AE, Brenner MK, Dotti G. Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2008 Sep; 21(3):375-89. PMID: 18790444; PMCID: PMC2758265.
    29. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5. PMID: 18463534; PMCID: PMC2745436.
    30. Kaka AS, Foster AE, Weiss HL, Rooney CM, Leen AM. Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother. 2008 May; 31(4):359-69. PMID: 18391760; PMCID: PMC2744357.
    31. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802. PMID: 17638856; PMCID: PMC2018664.
    32. Foster AE, Leen AM, Lee T, Okamura T, Lu A, Vera J, Atkinson R, Bollard CM, Dotti G, Rooney CM. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007 Jul-Aug; 30(5):506-16. PMID: 17589291.
      View in: PubMed
    33. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 1; 110(7):2620-30. PMID: 17507664; PMCID: PMC1988944.
    34. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, Shaw P, Bradstock K, Gottlieb D. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):707-14. PMID: 17531781.
      View in: PubMed
    35. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-65. PMID: 17129181.
      View in: PubMed
    36. Leen A, Ratnayake M, Foster A, Heym K, Ahmed N, Rooney CM, Gottschalk S. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107. PMID: 17198088.
      View in: PubMed
    37. Foster AE, Rooney CM. Improving T cell therapy for cancer. Expert Opin Biol Ther. 2006 Mar; 6(3):215-29. PMID: 16503732.
      View in: PubMed
    38. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 1; 11(19 Pt 1):6916-23. PMID: 16203783.
      View in: PubMed
    39. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 2005 Feb; 4(2):203-5. PMID: 15655356.
      View in: PubMed
    40. Foster AE, Bradstock KF, Sili U, Marangolo M, Rooney CM, Gottlieb DJ. A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors. Biol Blood Marrow Transplant. 2004 Nov; 10(11):761-71. PMID: 15505607.
      View in: PubMed
    41. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33. PMID: 15381773; PMCID: PMC521140.
    42. Foster AE, Marangolo M, Sartor MM, Alexander SI, Hu M, Bradstock KF, Gottlieb DJ. Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood. 2004 Oct 15; 104(8):2403-9. PMID: 15231569.
      View in: PubMed
    43. Foster AE, Forrester K, Gottlieb DJ, Barton GW, Romagnoli JA, Bradstock KF. Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture. Biotechnol Bioeng. 2004 Jan 20; 85(2):138-46. PMID: 14704996.
      View in: PubMed
    44. Foster AE, Forrester K, Li YC, Gottlieb DJ. Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer. Curr Pharm Des. 2004; 10(11):1207-20. PMID: 15078136.
      View in: PubMed
    45. Foster AE, Gottlieb DJ, Marangolo M, Bartlett A, Li YC, Barton GW, Romagnoli JA, Bradstock KF. Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy. J Hematother Stem Cell Res. 2003 Feb; 12(1):93-105. PMID: 12662440.
      View in: PubMed
    46. Foster AE, Gottlieb DJ, Sartor M, Hertzberg MS, Bradstock KF. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(9):501-11. PMID: 12374455.
      View in: PubMed
    FOSTER's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _